Therefore, growth curves of untreated MDS/CMML and AML cells were correlated with the corresponding surviving fractions of talazoparib and APE1 inhibitor III treated MDS/CMML and AML cells (Figure 1C,D). This evidence concerns the gene APEX1 and acute myeloid leukemia.